A role for rituximab in depleting B cells and compromising their antigen ... Type II mixed essential CRYOGLOBULINEMIA (MEC) is often associated with hepatitis C virus (HCV) infection, and leads ...

Patients receiving B cell-depleting agents (E.g., rituximab), chimeric antigen receptor (CAR)-T cell therapies, or cytokine/integrin inhibitors. Patients receiving tyrosine kinase inhibitor (TKI ...

By Dr. Liji Thomas, MD New recommendations address advances in immunosuppressive therapies and highlight antiviral prophylaxis for high-risk patients. Study: AGA Clinical Practice Guideline on the ...

hepatitis B reactivation, hepatotoxicity, possible malignancies, hematologic events, neurologic events and lupus-like syndrome Rituximab (Rituxan®) Infusion reactions, nausea, upper respiratory ...

Indeed, selective depletion of B lymphocytes prevented the onset of autoimmune diabetes in these mice. Pescovitz was aware that rituximab—a chimeric anti-CD20 monoclonal antibody developed to ...